MX362839B - Método para estabilizar suspensiones de glóbulos rojos que encapsulan un ingrediente activo, y suspensiones obtenidas. - Google Patents
Método para estabilizar suspensiones de glóbulos rojos que encapsulan un ingrediente activo, y suspensiones obtenidas.Info
- Publication number
- MX362839B MX362839B MX2015015374A MX2015015374A MX362839B MX 362839 B MX362839 B MX 362839B MX 2015015374 A MX2015015374 A MX 2015015374A MX 2015015374 A MX2015015374 A MX 2015015374A MX 362839 B MX362839 B MX 362839B
- Authority
- MX
- Mexico
- Prior art keywords
- suspension
- suspensions
- active ingredient
- solution
- blood cells
- Prior art date
Links
- 239000000725 suspension Substances 0.000 title abstract 8
- 210000003743 erythrocyte Anatomy 0.000 title abstract 6
- 239000004480 active ingredient Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000003019 stabilising effect Effects 0.000 title 1
- 239000000243 solution Substances 0.000 abstract 4
- 238000011534 incubation Methods 0.000 abstract 3
- 206010018910 Haemolysis Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000003297 denaturating effect Effects 0.000 abstract 1
- 230000008588 hemolysis Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 239000003761 preservation solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona un método para obtener una suspensión estabilizada de glóbulos rojos que encapsulan un ingrediente activo, de los RBCs resellados que incorporan el ingrediente activo, el método comprende la incubación de los RBCs resellados en una solución de incubación a una osmolalidad no menor que 280 mOsmol/kg, durante un intervalo de tiempo de 30 minutos o mayor, la solución de incubación que es una solución que no contiene un agente que es desnaturalizante para la membrana de RBC, el medio líquido es removido entonces de la suspensión incubada y los RBCs obtenidos son colocados en suspensión en una solución que permite la inyección de la suspensión en un paciente. Las suspensiones obtenidas están caracterizadas particularmente por un nivel de hemoglobina extracelular mantenido en 0.5 o inferior, en particular 0.2 g/dl o inferior y/o una velocidad de la hemólisis mantenida en 2 o menor, en particular 1 % o menor, a 72 h después de colocarla en suspensión en una solución de conservación y a una temperatura de entre 2 y 8 °C.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1354204A FR3005420B1 (fr) | 2013-05-07 | 2013-05-07 | Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues. |
| PCT/EP2014/059327 WO2014180897A1 (en) | 2013-05-07 | 2014-05-07 | Method for stabilising suspensions of red blood cells encapsulating an active ingredient, the suspensions obtained |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015015374A MX2015015374A (es) | 2016-06-02 |
| MX362839B true MX362839B (es) | 2019-02-19 |
Family
ID=49378358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015015374A MX362839B (es) | 2013-05-07 | 2014-05-07 | Método para estabilizar suspensiones de glóbulos rojos que encapsulan un ingrediente activo, y suspensiones obtenidas. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10286008B2 (es) |
| EP (1) | EP2994116B1 (es) |
| JP (1) | JP6625970B2 (es) |
| KR (1) | KR102013731B1 (es) |
| CN (1) | CN105246467B (es) |
| AU (1) | AU2014264650B2 (es) |
| BR (1) | BR112015028054A2 (es) |
| CA (1) | CA2910975C (es) |
| CL (1) | CL2015003273A1 (es) |
| ES (1) | ES2729343T3 (es) |
| FR (1) | FR3005420B1 (es) |
| IL (1) | IL242468B (es) |
| JO (1) | JO3549B1 (es) |
| MX (1) | MX362839B (es) |
| RU (1) | RU2668688C2 (es) |
| SG (1) | SG11201509062RA (es) |
| TR (1) | TR201908017T4 (es) |
| WO (1) | WO2014180897A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3071515A2 (en) | 2013-11-18 | 2016-09-28 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| FR3017299B1 (fr) | 2014-02-12 | 2018-05-18 | Erytech Pharma | Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur |
| HUE054471T2 (hu) | 2014-04-01 | 2021-09-28 | Rubius Therapeutics Inc | Immunmodulációs módszerek és készítmények |
| EP3187190A1 (en) | 2015-12-31 | 2017-07-05 | Erytech Pharma | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion |
| MX2018008515A (es) | 2016-01-11 | 2019-05-09 | Rubius Therapeutics Inc | Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones inmunitarias. |
| EP3496743B1 (en) | 2016-08-08 | 2022-02-09 | AERase, Inc. | Compositions and methods for treating cancer with arginine depletion and immuno oncology agents |
| WO2019042628A1 (en) | 2017-08-31 | 2019-03-07 | Erytech Pharma | ARGININE DEIMINASE ENCAPSULATED WITHIN ERYTHROCYTES AND THEIR USE IN THE TREATMENT OF CANCER AND ARGINASE-1 DEFICIENCY |
| EP3449935A1 (en) * | 2017-08-31 | 2019-03-06 | Erytech Pharma | Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency |
| MX2020005933A (es) | 2017-12-05 | 2021-01-15 | Aerase Inc | Metodo y composicion para tratar la deficiencia de arginasa 1. |
| CA3116736A1 (en) | 2018-10-19 | 2020-04-23 | Aerase, Inc. | Arginine depletion therapy for treatment of gamt deficiency |
| JP7257182B2 (ja) * | 2019-02-27 | 2023-04-13 | 京セラ株式会社 | 検査装置および検査方法 |
| US20210189371A1 (en) | 2019-08-30 | 2021-06-24 | Aeglea Biotherapeutics, Inc. | Methods For Production Of Human Recombinant Arginase 1 And Uses Thereof |
| EP4147730A1 (en) * | 2021-09-09 | 2023-03-15 | ETH Zurich | Method of preparing a functional hydrogel material that can be injected |
| WO2023067200A1 (en) | 2021-10-24 | 2023-04-27 | Erytech Pharma | Asparaginase encapsulated in red blood cells for the treatment of pancreatic cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2655801C2 (de) * | 1976-12-09 | 1986-06-26 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | Injizierbare Suspension von Membranvesikeln aus Erythrozyten und Verfahren zur Herstellung der Suspension |
| DE2740053A1 (de) | 1977-09-06 | 1979-05-03 | Klaus Prof Dr Med Gersonde | Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten |
| US4327710A (en) | 1980-06-18 | 1982-05-04 | The United States Of America As Represented By The Secretary Of Agriculture | Process for encapsulating additives in resealed erythrocytes for disseminating chemicals via the circulatory system |
| US4389209A (en) * | 1980-06-18 | 1983-06-21 | The United States Of America As Represented By The Secretary Of Agriculture | Method of providing systemic protection from bloodsucking insects and other parasites using encapsulated additives in resealed erythrocytes |
| FR2529463B1 (fr) | 1982-07-05 | 1986-01-10 | Centre Nat Rech Scient | Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus |
| US4478824A (en) | 1983-08-08 | 1984-10-23 | Franco Robert S | Method for altering red blood cell function and survival |
| US4801777A (en) | 1987-09-03 | 1989-01-31 | Vanderbilt University | Blood rewarming method and apparatus |
| FR2660864A1 (fr) * | 1990-04-13 | 1991-10-18 | Guerbet Sa | Composition de contraste, procede de preparation de cette composition et application a l'imagerie. |
| FR2678512B1 (fr) | 1991-07-03 | 1995-06-30 | Novacell | Machine a internaliser. |
| AU680890B2 (en) | 1993-03-23 | 1997-08-14 | Cbr Laboratories, Inc. | Method and apparatus for encapsulation of biologically-active substances in cells |
| FI963978L (fi) | 1994-04-05 | 1996-12-02 | North Gen Hospital Nhs Trust | Solususpensioiden preparointi ja stabilointi |
| DE69732225T2 (de) * | 1997-05-05 | 2005-06-23 | Dideco S.R.L., Mirandola | Verfahren zur Verkapselung von biologisch aktiven Stoffen in Erythrocyten und Gerät dafür |
| US6610702B2 (en) | 2000-08-01 | 2003-08-26 | Gmp Oxycell, Inc. | Ammonium salts of inositol hexaphosphate, and uses thereof |
| RU2271540C2 (ru) * | 2003-07-21 | 2006-03-10 | Ставропольский научно-иследовательский противочумный институт | Способ получения биомагноиммуносорбента для обнаружения бактериальных антигенов (варианты) |
| FR2873925B1 (fr) | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
| FR2884717B1 (fr) * | 2005-04-25 | 2009-07-03 | Erytech Pharma Soc Par Actions | Erythrocytes renfermant de l'arginine deiminase |
| UA97234C2 (ru) * | 2005-11-01 | 2012-01-25 | Уайєт | Раствор хлорида натрия для восстановления влагосодержания композиции лиофилизированного фактора ix |
| FR2928270B1 (fr) | 2008-03-10 | 2011-01-21 | Erytech Pharma | Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os |
| FR2938332B1 (fr) | 2008-11-07 | 2011-11-25 | Erytech Pharma | Test predictif de la neutralisation de l'activite asparaginase |
-
2013
- 2013-05-07 FR FR1354204A patent/FR3005420B1/fr active Active
-
2014
- 2014-05-05 JO JOP/2014/0156A patent/JO3549B1/ar active
- 2014-05-07 BR BR112015028054A patent/BR112015028054A2/pt not_active Application Discontinuation
- 2014-05-07 TR TR2019/08017T patent/TR201908017T4/tr unknown
- 2014-05-07 EP EP14726095.4A patent/EP2994116B1/en active Active
- 2014-05-07 KR KR1020157034227A patent/KR102013731B1/ko active Active
- 2014-05-07 RU RU2015152127A patent/RU2668688C2/ru active
- 2014-05-07 WO PCT/EP2014/059327 patent/WO2014180897A1/en not_active Ceased
- 2014-05-07 SG SG11201509062RA patent/SG11201509062RA/en unknown
- 2014-05-07 CA CA2910975A patent/CA2910975C/en active Active
- 2014-05-07 AU AU2014264650A patent/AU2014264650B2/en not_active Ceased
- 2014-05-07 US US14/889,083 patent/US10286008B2/en active Active
- 2014-05-07 JP JP2016512361A patent/JP6625970B2/ja not_active Expired - Fee Related
- 2014-05-07 MX MX2015015374A patent/MX362839B/es active IP Right Grant
- 2014-05-07 CN CN201480025939.1A patent/CN105246467B/zh not_active Expired - Fee Related
- 2014-05-07 ES ES14726095T patent/ES2729343T3/es active Active
-
2015
- 2015-11-05 IL IL242468A patent/IL242468B/en active IP Right Grant
- 2015-11-06 CL CL2015003273A patent/CL2015003273A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN105246467A (zh) | 2016-01-13 |
| KR20160005077A (ko) | 2016-01-13 |
| MX2015015374A (es) | 2016-06-02 |
| IL242468B (en) | 2020-03-31 |
| JO3549B1 (ar) | 2020-07-05 |
| JP6625970B2 (ja) | 2019-12-25 |
| RU2015152127A (ru) | 2017-06-13 |
| CA2910975A1 (en) | 2014-11-13 |
| US20160095884A1 (en) | 2016-04-07 |
| CN105246467B (zh) | 2018-11-27 |
| AU2014264650A1 (en) | 2015-11-19 |
| CL2015003273A1 (es) | 2016-05-27 |
| BR112015028054A2 (pt) | 2017-07-25 |
| EP2994116A1 (en) | 2016-03-16 |
| AU2014264650B2 (en) | 2018-10-18 |
| JP2016517899A (ja) | 2016-06-20 |
| TR201908017T4 (tr) | 2019-06-21 |
| SG11201509062RA (en) | 2015-12-30 |
| CA2910975C (en) | 2020-01-21 |
| FR3005420B1 (fr) | 2015-09-18 |
| RU2015152127A3 (es) | 2018-03-30 |
| KR102013731B1 (ko) | 2019-08-23 |
| FR3005420A1 (fr) | 2014-11-14 |
| US10286008B2 (en) | 2019-05-14 |
| EP2994116B1 (en) | 2019-03-06 |
| WO2014180897A1 (en) | 2014-11-13 |
| HK1218714A1 (zh) | 2017-03-10 |
| RU2668688C2 (ru) | 2018-10-02 |
| ES2729343T3 (es) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX362839B (es) | Método para estabilizar suspensiones de glóbulos rojos que encapsulan un ingrediente activo, y suspensiones obtenidas. | |
| CY1124447T1 (el) | Ιατροτεχνολογικο προϊον το οποιο περιεχει μια συνθεση πλακουντα η οποια συνισταται σε αριπιπραζολη ως δραστικη ουσια, και μια συνθεση πλακουντα η οποια συνισταται σε αριπιπραζολη ως δραστικη ουσια | |
| WO2012121523A3 (en) | Process for preparing pharmaceutical formulation in form of antioxidant-free solution for injection containing pemetrexed or its salt | |
| CA2817172C (en) | Stem cell suspension | |
| PH12017500837A1 (en) | Container containing a nicotine solution | |
| WO2012019103A3 (en) | System and apparatus for cell treatment | |
| BR112015005878A2 (pt) | nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas | |
| PH12015502722B1 (en) | Trehalose and dextran-containing solution for transplanting mammalian cells | |
| PH12013502104A1 (en) | Creamers and methods of making same | |
| EP3309873A4 (en) | ANODEACTIVE MATERIAL FOR LITHIUM SECONDARY BATTERY, METHOD OF MANUFACTURING THEREOF AND LITHIUM SUBSTITUTING BATTERY THEREWITH | |
| WO2012075041A3 (en) | Method of blood pooling and storage | |
| SA517390475B1 (ar) | نظام أكياس متعددة وطريقة لتحضير مكونات الدم | |
| EP4631569A3 (en) | Alginate film comprising a triptan | |
| NZ731204A (en) | Lactase solution and milk using same | |
| BR112017004017A2 (pt) | sistema de fermentação para processos de moagem seca | |
| WO2012097190A3 (en) | Tissue preservation at room temperature and tissue preservation system | |
| WO2015117764A8 (en) | Dry acid concentrate in granulate form | |
| SG11201901617PA (en) | Azole compound ophthalmic preparation | |
| PH12014501034A1 (en) | Liquid creamers and methods of making same | |
| SG10201900476YA (en) | Carrier structure, drug carrier, and manufacturing method and use thereof | |
| RU2011101134A (ru) | Способ уничтожения зарослей борщевика сосновского | |
| ZHU et al. | The protective effects of CD4+ CD25+ Treg cell on the allograft after infusion of dendritic cells with low expression of CD40 from donor in mouse heart transplantation | |
| AU2015242879A1 (en) | Melatonin secretion regulator, and method for regulating melatonin secretion | |
| UA74165U (ru) | Способ подготовки ядросодержащих клеток пуповинной/ плацентарной крови к криоконсервированию | |
| UA102518U (uk) | Спосіб моделювання впливу диклофенаку натрію на показники червоного кісткового мозку щурів в експерименті |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |